Citations

Clear

24 citation(s) found for "David, William".

Accuracy, readability, and health information quality of AI chatbot responses for patient education on intermittent fasting in chronic kidney disease: a prospective structured evaluation
Shah, Joel , Wells-Gatnik, William, Palmer, Biff, Acharya, Prakrati, Cheungpasitporn, Wisit, Wells-Gatnik, William David , Cheungpasitporn, Wisit

Mayo Clinic

Frontiers in Nephrology | May 29, 2026 | Volume: 6 | Issue: No issue available | Pages: No page available

10.3389/fneph.2026.1857793 | PMID 42290829 Get It

Background Intermittent fasting (IF) represents a dietary strategy with known metabolic benefits, however its safety and applicability in patients with chronic kidney disease (CKD) remains poorly understood. AI chatbots’ reliability for clinical and dietary guidance in clinically complex areas remains underexplored. No study has examined AI performance on IF in patients with CKD. This study evaluated the accuracy, consistency, readability, and quality of responses generated by ChatGPT-5 and Claude 4.5 Sonnet regarding IF in CKD. Methods Twenty-five patient-centered questions spanning seven clinical domains were developed by two board-certified nephrologists and submitted independently to ChatGPT-5 and Claude 4.5 Sonnet twice per model. Prompts were submitted under standard and unmodified user conditions without customized system instructions to represent a zero-shot evaluation that is illustrative of typical patient use. Responses were evaluated for accuracy, consistency (comparatively between responses), and appropriateness by the evaluators. Response readability and quality were assessed using the Flesch-Kincaid Grade Level (FKGL) formula and the DISCERN instrument respectively. Results Both ChatGPT-5 and Claude 4.5 Sonnet demonstrated identical accuracy scores during the first question prompts with notable improvement upon re-prompting after 24-hours. Both models demonstrated an identical internal consistency at 90%. ChatGPT-5 produced responses at the middle school level, better aligned with the US adult health literacy benchmark, while Claude 4.5 Sonnet generated responses at the high school level. DISCERN scoring was comparable between chatbots indicative of good response quality. Both chatbots had similar performance regarding individual subdomains. Conclusions Both chatbots illustrated clinically accurate and cautious responses to questions regarding IF in CKD. ChatGPT-5 responses were better suited to the average health literacy of the general United States adult population. Despite our findings, we do not recommend either chatbot be used as the primary source for clinical counseling regarding IF in CKD. It is important for clinicians to help to guide patients toward evidence-based clinical information.
Shape-sensing robotic-assisted bronchoscopy with integrated mobile cone-beam CT for small nodules: results from the prospective multicentre CONFIRM study
Husta, Bryan C, Cheng, George Z. , Batra, Hitesh , Reisenauer, J., Bartek, William, Kalchiem‐Dekel, Or , Zouk, Aline, Patel, Niral, Chawla, Mohit, Eapen, George A. , Jiménez, C. Delgado, Lee, R. J., Bott, Matthew J. , Oh, Scott , Casal, Roberto F, Casal, Roberto , Reisenauer, Janani , Zouk, Aline N., Patel, Niral M. , Chawla, Mohit , Casal, Roberto F.

Mayo Clinic

Thorax | February 16, 2026 | Volume: 81 | Issue: 3 | Pages: 267-275

10.1136/thorax-2025-223272 | PMID 41698810 Get It

Background The use of 3D imaging with navigation bronchoscopy has increased with the introduction of mobile cone-beam CT (mCBCT). Shape-sensing robotic-assisted bronchoscopy (ssRAB) integrated with mCBCT has been introduced to correct for CT to body divergence (CT-BD) during the biopsy of peripheral pulmonary nodules (PPNs). Methods Prospective observational multicentre study, enrolling patients with a PPN of ≤20 mm suspicious for malignancy, assessing tool-in-lesion (TIL), diagnostic yield, sensitivity for malignancy and incidence of pneumothorax or airway bleeding. Non-malignant index biopsies were followed for 12 months. Descriptive statistics are reported for all variables along with 95% CI for primary endpoints. Results 155 consecutive patients were enrolled at six centres. Median nodule size was 14.0 mm (IQR 11.0–17.0), with 54.8% of nodules (85/155) in the upper lobes, 25.8% (40/155) with CT bronchus sign present and median distance to the nearest pleural surface of 8.2 mm (IQR 1.8–20.0). TIL was achieved in 154/155 (99.4%, 95% CI 96.5 to 100.0) procedures. A median of two (IQR 1–3) mCBCT spins were performed, with median dose area product of 25.7 Gy · cm 2 (IQR 11.0–46.7). Diagnostic yield per the American Thoracic Society/American College of Chest Physicians (ATC/ACCP) definition was 89.0% (n=138/155; 95% CI 83.0 to 93.5) and sensitivity for malignancy was 91.5% (95% CI 86.4 to 96.5). No pneumothorax (0%, 95% CI 0.0 to 2.4) and two Nashville Grade three bleeding events were reported (1.3%, 95% CI 0.2 to 4.6). Interpretation The first prospective multicentre study of integrated ssRAB and mCBCT for small peripheral nodules resulted in diagnostic outcomes similar to those reported for transthoracic biopsy with a more favourable safety profile. Trial registration number ClinicalTrials.gov ID: NCT05562895 .
A Wearable Multimodal Vital Sign Detection and Photobiomodulation Device for Early Brain Injury Treatment: A Feasibility Study
Kantor, Debbie , Blaivas, Michael , Kantor, Elliot, Greer, Jennifer, Mitra, Kunal , Raj, Mercy Golda Sam, Moore, Caroline , Dong, Yajie , Freeman, William David, Greer, Jennifer, Raj, Mercy Golda Sam, Freeman, William D.

Mayo Clinic

Military Medicine | September 19, 2025 | Volume: 190 | Issue: Supplement_2 | Pages: 387-393

10.1093/milmed/usaf201 | PMID 40984082 Get It

ABSTRACT Traumatic brain injury (TBI), particularly among military personnel, poses significant challenges in acute management and long-term outcomes. Difficult-to-diagnose autoregulatory and inflammatory changes lead to neurocognitive impairment, anxiety, sleep disturbance, and chronic pain. To optimize readiness and test therapeutics for both diagnostic and future TBI treatments, this feasibility study introduces a novel wearable multimodal platform that integrates photoplethysmography and infra-red (IR) sensing from a camera and a wearable sensor to detect vital signs and then leverages machine learning (ML) to predict the need for acute treatment. This prospective observational study involving 28 healthy volunteers simulated a triage emergency room workflow to test sensor accuracy and mobile app functionality. The wearable device demonstrated high accuracy in pulse rate (mean error 7.3%) and oxygen saturation (mean error −1.2%) compared to standard-of-care devices. Camera-based pulse and respiratory rate, and wearable pulse, oxygen, and temperature sensing were tested in a mock triage setting to simulate activation of light-based treatment upon detection of physiological changes of concern after acute TBI. Preliminary ML models to predict hypotension and pain based on retrospective data achieved 98.4% and 93% accuracy but showed limitations in prospective real-time applications. This study provided insights to prepare for future iterations that will integrate near-IR spectroscopy to detect cerebral oximetry, and quantum dot light-emitting diodes to activate light-based treatment (photobiomodulation) from within a wearable head dressing. The findings underscore the potential of this platform to bridge critical gaps in acute TBI care through early detection and future therapeutic intervention. Further development is needed to address environmental challenges, improve accuracy across diverse populations, and refine the device for real-time clinical use. This innovative approach has the potential to revolutionize TBI care by bridging current gaps in diagnostic and therapeutic management.
Predictors of treatment response and overall survival in patients with breast cancer brain metastases treated with stereotactic radiosurgery: a prospective study using the NeuroPoint Alliance SRS Registry
D’Ambrosio, Anthony, Cobb, William S., Grills, Inga S., McInerney, James , Jensen, Randy L. , Chang, Eric L. , Timmerman, Robert , Attia, Albert, Spalding, Aaron C., Walter, Kevin A. , Bydon, Mohamad , Asher, Anthony L. , Sheehan, Jason P. , Katsos, Konstantinos, Katsos, Konstantinos, Michalopoulos, Giorgos D. , Cobb, William S., Andrews, David William , Pouratian, Nader

Mayo Clinic

Journal of Neurosurgery | June 27, 2025 | Volume: 143 | Issue: 5 | Pages: 1419-1430

10.3171/2025.3.jns241471 | PMID 40577855 Get It

OBJECTIVE The aim of this study was to evaluate mortality and progression outcomes in patients undergoing stereotactic radiosurgery (SRS) for breast cancer brain metastases and to identify associated risk factors using a national quality registry. METHODS The NeuroPoint Alliance (NPA) SRS Registry was employed for this study, which conducted prospective enrollment of patients undergoing SRS at 16 participating centers from 2017 to 2024. Outcomes of interest included the post-SRS EQ-5D score change, overall survival, local progression, out-of-field progression, and overall intracranial progression. For all time-to-event analyses, Kaplan-Meier curves and multivariable Cox regressions with hazard ratios were used. RESULTS A total of 138 patients (127 female, mean age 59.8 years) were identified; 46.4% had a single lesion, 42.0% had 2–4 lesions, and 11.6% had ≥ 5 lesions, while 87.0% had a Karnofsky Performance Status (KPS) score between 80 and 100. The median overall survival was 17.9 months, and independent predictors of all-cause mortality included a KPS score ≤ 90 (HR 6.73) and diabetes mellitus (HR 3.35). The median time to local progression was 19.8 months. More than 5 lesions at baseline (HR 9.03) and a marginal dose ≤ 17.6 Gy (HR 8.00) were predictive of local recurrence. The median was not reached for out-of-field progression, and predictors included ≥ 2 lesions at the time of SRS (HR 3.20) and a marginal dose ≤ 17.6 Gy (HR 4.61). At the final follow-up assessment, 17.1% of patients experienced no change according to the EQ-5D, while 34.3% had improvement, 11.4% had mixed results, and 37.1% had worsened health. In the multivariable linear regression model, pre-SRS resection (r = 1.92) and baseline EQ-5D score (r = 1.29) were statistically significant predictors of quality of life at the final follow-up assessment. CONCLUSIONS Using real-world data from the NPA SRS Registry, this study demonstrated comparable outcomes in patients who underwent SRS for breast cancer brain metastases compared with those of previous literature. The number of lesions at the time of SRS and the marginal dose were independent risk factors for local recurrence, out-of-field progression, and overall intracranial progression. Pre-SRS resection and baseline EQ-5D score were independent predictors of quality of life following SRS.
Immune checkpoint inhibitor related neurologic adverse events: clinical spectrum, management and outcomes (S21.003)
David, William, Reynolds, Kerry L. , Chute, Donald F., Clement, Nathan F., Mooradian, Meghan J. , Sullivan, Ryan J. , Guidon, Amanda C. , Dubey, Divyanshu , Cohen, Justine Vanessa , Lawrence, Donald P.

Mayo Clinic

Neurology | December 7, 2023 | Volume: 92 | Issue: 15_supplement | Pages: No page available

10.1212/wnl.92.15_supplement.s21.003 Get It

RTID-08. A RANDOMIZED, MULTICENTER, DOUBLE-BLIND, PHASE 2B STUDY OF IGV-001, AN AUTOLOGOUS CELL IMMUNOTHERAPY WITH ANTISENSE OLIGO IMV-001 TARGETING IGF-1R, VS PLACEBO, IN NEWLY DIAGNOSED GLIOBLASTOMA PATIENTS
Judy, Kevin , Schulder, Michael , Hanft, Simon , Evans, Linton T. , Wu, Julian K. , Agarwal, Vijay , Ramakrishna, Rohan , Elder, J. Bradley , Quiñones‐Hinojosa, Alfredo , Pérez‐Ollé, Raül, Diwanji, Madhavi, Pennock, Gregory, Scott, Charles , Boockvar, John A. , Lee, Ian , Aulakh, Sonikpreet , Wong, Eric T. , Gill, Brian J. A. , Brennan, Cameron , Andrews, David William

Mayo Clinic

Neuro-Oncology | November 11, 2023 | Volume: 25 | Issue: Supplement_5 | Pages: v260-v260

10.1093/neuonc/noad179.0999 Get It

Abstract Glioblastoma (GBM) is the most common primary brain malignancy in adults. Standard of care (SOC) for suspected GBM begins with maximal safe resection followed by adjuvant radiotherapy and temozolomide, and maintenance temozolomide. Imvax has developed the Goldspire™ platform to create IGV-001, an autologous biologic-device combination product for the treatment of newly diagnosed GBM (ndGBM). IGV-001 consists of autologous GBM tumor cells and an antisense oligonucleotide against IGF-1R mRNA (IMV-001), irradiated and administered via biodiffusion chambers implanted in the abdomen. Together, these components stimulate immunogenic cell death and antigen release. IGV-001 was well tolerated and multiple efficacy signals were observed in a Phase 1b study in patients with ndGBM, including significant improvements in progression-free survival (PFS), radiographic evidence of tumor response, and changes in immune response biomarkers. A Phase 2b randomized, multicenter, double-blind, placebo-controlled study has been initiated to assess the safety and efficacy of IGV-001 in patients with ndGBM (NCT04485949). After surgical resection, patients will be treated with IGV-001 or placebo followed by SOC. 25 US sites have been selected with a target enrollment of 93 patients (2:1 randomization) and the study is open to enrollment. Key inclusion criteria are 18 to 70 years of age, Karnofsky performance status score ≥ 70, diagnosis of GBM based on the treating neurosurgeon's best clinical judgement, confirmed measurable disease pre-operatively, tumor located in the supratentorial compartment, and adequate bone marrow and organ function. Key exclusion criteria include bihemispheric disease, multicentric disease, or treatment with Tumor Treating Fields prior to documented progression. The primary outcome is PFS, defined as the time from randomization to first progression, as determined by blinded central radiology review, or death. Secondary outcomes include overall survival, defined as the time from randomization to death due to any cause, and safety.
Stereotactic radiosurgery in the management of non–small cell lung cancer brain metastases: a prospective study using the NeuroPoint Alliance Stereotactic Radiosurgery Registry
Michalopoulos, Giorgos D. , Grills, Inga S., Warnick, Ronald E. , McInerney, James , Attia, Albert, Timmerman, Robert , Chang, Eric L. , D’Ambrosio, Anthony, Cobb, William S., Spalding, Aaron C., Walter, Kevin A. , Jensen, Randy L. , Bydon, Mohamad , Asher, Anthony L. , Sheehan, Jason P. , Katsos, Konstantinos, Michalopoulos, Giorgos , Katsos, Konstantinos, Andrews, David William , Cobb, William S., Pouratian, Nader

Mayo Clinic

Journal of Neurosurgery | November 11, 2023 | Volume: 140 | Issue: 5 | Pages: 1223-1232

10.3171/2023.8.jns23308 | PMID 37948684 Get It

OBJECTIVE The literature on non–small cell lung cancer (NSCLC) brain metastases (BMs) managed using stereotactic radiosurgery (SRS) relies mainly on single-institution studies or randomized controlled trials (RCTs). There is a literature gap on clinical and radiological outcomes of SRS for NSCLC metastases in real-world practice. The objective of this study was to benchmark mortality and progression outcomes in patients undergoing SRS for NSCLC BMs and identify risk factors for these outcomes using a national quality registry. METHODS The SRS Registry of the NeuroPoint Alliance was used for this study. This registry included patients from 16 enrolling sites who underwent SRS from 2017 to 2022. Data are prospectively collected without a prespecified research purpose. The main outcomes of this analysis were overall survival (OS), out-of-field recurrence, local progression, and intracranial progression. All time-to-event investigations included Kaplan-Meier analyses and multivariable Cox regressions. RESULTS Two hundred sixty-four patients were identified, with a mean age of 66.7 years and a female proportion of 48.5%. Most patients (84.5%) had a Karnofsky Performance Status (KPS) score of 80–100, and the mean baseline EQ-5D score was 0.539 quality-adjusted life years. A single lesion was present in 53.4% of the patients, and 29.1% of patients had 3 or more lesions. The median OS was 28.1 months, and independent predictors of mortality included no control of primary tumor (hazard ratio [HR] 2.1), KPS of 80 (HR 2.4) or lower (HR 2.4), coronary artery disease (HR 2.8), and 5 or more lesions present at the time of SRS treatment (HR 2.3). The median out-of-field progression-free survival (PFS) was 24.8 months, and the median local PFS was unreached. Intralesional hemorrhage was an independent risk factor of local progression, with an HR of 6.0. The median intracranial PFS was 14.0 months and was predicted by the number of lesions at the time of SRS (3–4 lesions, HR 2.2; 5–14 lesions, HR 2.5). CONCLUSIONS In this real-world prospective study, the authors used a national quality registry and found favorable OS in patients with NSCLC BMs undergoing SRS compared with results from previously published RCTs. The intracranial PFS was mainly driven by the emergence of new lesions rather than local progression. A greater number of lesions at baseline was associated with out-of-field progression, while intralesional hemorrhage at baseline was associated with local progression.
Does Initiation of Prophylactic Antiseizure Medication Improve Neurological Outcomes in Patients With Acute Intracerebral Hemorrhage?
Crepeau, Amy Z. , Knox, Molly G., Sánchez, Cristina Valencia, Marks, Lisa , O’Carroll, Cumara B. , Freeman, William David, Valencia Sanchez, Cristina, O'Carroll, Cumara B., Marks, Lisa A , Chhabra, Nikita , Demaerschalk, Bart M. , Freeman, William D.

Mayo Clinic

The Neurologist | November 3, 2023 | Volume: 28 | Issue: 6 | Pages: 422-425

10.1097/nrl.0000000000000537 | PMID 37922729 Get It

Objective: The objective of this study was to critically assess current evidence regarding the role of prophylactic antiseizure medication in patients presenting with acute intracerebral hemorrhage (ICH). Methods: The objective was addressed through the development of a structured critically appraised topic. This included a clinical scenario with a clinical question, literature search strategy, critical appraisal, results, evidence summary, commentary, and bottom-line conclusions. Participants included resident neurologists, a medical librarian, and content experts in the fields of epilepsy, stroke neurology, neurohospitalist medicine, and neurocritical care. Results: A randomized clinical trial was selected for critical appraisal. The trial assessed whether prophylactic levetiracetam (LEV) use reduced the risk of acute seizures in patients with ICH, as defined by clinical or electrographic seizure, captured by continuous electroencephalogram 72 hours after enrollment. A total of 42 patients were included in the final analysis (19 in the LEV group and 23 in the placebo group). There was a significantly higher occurrence of seizures in the placebo versus LEV group (LEV 16% vs placebo 43%, P = 0.043). There were no differences in functional outcomes between the groups at 3, 6, or 12 months (P > 0.1). Conclusions: The role of prophylactic treatment with antiseizure medication in ICH remains unclear.
Severe Neurological Toxicity of Immune Checkpoint Inhibitors: Growing Spectrum
Dubey, Divyanshu , David, William S., Reynolds, Kerry L. , Chute, Donald F., Clement, Nathan F., Lawrence, Donald P. , Mooradian, Meghan J. , Sullivan, Ryan J. , Guidon, Amanda C. , Dubey, Divyanshu , Dubey, Divyanshu , Dubey, Divyanshu , Cohen, Justine Vanessa

Mayo Clinic

Annals of Neurology | February 22, 2020 | Volume: 87 | Issue: 5 | Pages: 659-669

10.1002/ana.25708 | PMID 32086972 Get It

Expanding use of immune‐checkpoint inhibitors (ICIs) underscores the importance of accurate diagnosis and timely management of neurological immune‐related adverse events (irAE‐N). We evaluate the real‐world frequency, phenotypes, co‐occurring immune‐related adverse events (irAEs), and long‐term outcomes of severe, grade III to V irAE‐N at a tertiary care center over 6 years. We analyze how our experience supports published literature and professional society guidelines. We also discuss these data with regard to common clinical scenarios, such as combination therapy, ICI rechallenge and risk of relapse of irAE‐N, and corticosteroid taper, which are not specifically addressed by current guidelines and/or have limited data. Recommendations for management and future irAE‐N reporting are outlined. ANN NEUROL 2020;87:659–669